Hello Bill. I would post a guess, but I have already been wrong. I predicted a partner announcement at the start of phase 3. I can't see how they can benefit by the delay, but I'd love to be wrong about that too! Also, if you have 30 min to kill, I'd love to know what you think about SNGX and the preliminary phase 2 results for the oral mucositis agent. The company market cap seems stupid cheap, or is it me that is stupid? I have been aggressively accumulating SNGX. Feel free to post any thoughts on the SNGX board, maybe I'll see you there.
Yes, I saw a segment on Bloomberg this weekend that mentioned Lessie Livermore. Certainly made me think back a few years!
You guys will need the paper and pen to jot down the license number of the truck that runs you over when they get a deal.......Oh, I will be on that truck.
Slakter said he would continue to buy shares regularly (credible). He said the SPA would be approved (credible). He said phase 3 will start after the SPA approval (credible). It smells like a partnership is coming........
Hi Bill. I was hoping you would reply. I agree it was odd not to be co-announced. I was also hoping it was for tactical decisions/negotiations as well. If we are correct, the second pop should be the bigger pop. Then, we just need to be concerned about how well the drops help visual acuity.
I'm not Anti-CTIX. I think Bralacidin is an interesting product. I think the market cap is warranted (or perhaps undervalued) for CTIX. I was stating SNGX will beat it to oral mucositis, which I think it will. Therefore, I think SNGX is very, very undervalued. Therefore, I am accumulating. How are you investing?
I am a physician and have been biotech investing for over a decade. Brilacidin by Cellceutix is an antibiotic with perhaps anti-inflammatory properties, that is what they are checking. The animal studies tswenor mentioned, looked very interesting but 942 is ahead and may have additional benefits (prevention of infection, better tumor response). I like the SNGX pipeline, that is why I'm here. I have been and continue to be accumulating. 23M market cap for the quality of the pipeline and the initial 942 data is much too low, IMHO.
Hi Reality, the desire of my patients (middle upper-class, well educated population), has been not to try inhaled insulin. You are correct, maybe there will not be any long term pulmonary toxicity after long term therapy......or maybe there will be.
Looks like CTIX is a 213M market cap. SNGX is 23M cap, so SNGX has the upside potential edge for sure. Also, check out all the lawsuits filed against CTIX for the CEO "hype". At least we don't have to deal with that mess.
I got bashed for posting this. I was correct, and did not buy the stock. (I should have shored MNKD but I did not). Now that MNKD is mostly out of the way, I may look at it again. I may add to my biotech stocks as well. Good luck to all.
17 disliked my post???? really???
users liked this posts
users disliked this posts
Potential investor question
by gs88gs88 • Aug 12, 2014 7:32 AM Remove
I have been considering an investment in SNY. I am especially optimistic on the PCSK9 cholesterol meds (I am a physician and treat lots of hyperlipidemia and lots of diabetes). I am personally less optimistic about inhaled insulin. I struggle with the unknown lung toxicity over longer periods of time and the injectable pens are easy for patients to use. So my question is, how will the stock do if the PCSK9 med is a hit and afrezza is a bit disappointing. I appreciate others thoughts on the investment potential IF (yes, it is an if, but I was ready to by SNY just before the MNKD deal, I stepped back) my scenario is correct
I agree fdaf....You can bet (I am), that the 942 will be unique, exciting and effective The big biotech sell off is providing an opportunity here. I bought handfuls of times under 110 and as low as 83. I have large limit buy in in the 70 cent range.